Musculoskeletal Medicine Market to Perceive Substantial Growth During 2018 - 2026

Platelet-Rich Plasma Emerging as an Effective Musculoskeletal Medicine
Platelet-rich plasma is one of the new developments in the expanding field of regenerative medicines. Specialists in the areas including physical medicines, rehabilitation, orthopedics, and rheumatology have been studying the benefits of the novel therapy and found platelet-rich plasma as a promising treatment in some of the musculoskeletal conditions. Due to the minimum clinical trials support, platelet-rich plasma still remains controversial, this calls for high quality clinical trials along with the long follow-up in shaping the perspective of this treatment option. However, with the increasing number of patients seeking non-surgical methods for the treatment of chronic and acute musculoskeletal disease and injury, is advancing the use of platelet-rich plasma.'

In recent years, chronic musculoskeletal pain has become a common medical condition among people. Although the treatment option for patients ranges from physical therapy to surgery, the higher chances of ineffectiveness, pain, and complications make these treatment options difficult. However, with the potential to change the face of musculoskeletal medicine, platelet-rich plasma and stem cell injections have emerged as better approaches in treating musculoskeletal disease with low risk of adverse reaction and complications.  

The use of platelet-rich plasma grafts to treat musculoskeletal disease has grown exponentially in last few years, it has also been proven effective in multiple other medical fields including podiatry, cosmetic surgery, neurosurgery, ENT, ophthalmology, wound healing, and urology. Growing media attention on the use of platelet-rich plasma in treating musculoskeletal disease has fueled the informed patient population and accelerating interest in this medicine. Moreover, platelet-rich plasma has also received media attention as it has largely been used by sports athletes to treat musculoskeletal injury.

A sample of this report is available upon request @  https://www.persistencemarketresearch.com/samples/22906

Platelet-rich plasma has also emerged as an effective treatment in healing multiple musculoskeletal issues. Recent studies have shown moderate to high quality evidence proving platelet-rich plasma’s positive effects in various conditions such as rotator cuff tendinopathy and lateral epicondylitis. Moreover, researchers have also found that to ensure effective treatment with platelet-rich plasma, various things need to be considered such as duration of symptoms, patient selection, and combination with other modalities such as physical therapy.

Moreover, clinical trials on the use of platelet-rich plasma including Leukocyte-rich platelet-rich plasma (LR-PRP) and Leukocyte-poor platelet-rich plasma (LS-PRP) have also been carried to provide evidence-based recommendation for various musculoskeletal issues. Most of the high quality evidence supports LR-PRP for various musculoskeletal conditions. However, there are insufficient evidences to recommend platelet-rich plasma for various conditions such as high ankle sprains, osteoarthritis of the hip, and rotator cuff tendinopathy. Moreover, recent evidences have also shown lack of efficacy of platelet-rich plasma for muscle injuries, ACL reconstruction, acute fracture, Achilles tendinopathy, and Achilles tendon repair. Another issue facing use of platelet-rich plasma in musculoskeletal disease and injury is the insurance reimbursement and academic acceptance both remaining largely reliant on positive and solid results from large and high quality clinical trials. 
Clinicians and researchers are focusing on new techniques in regenerative medicines at repairing and replacing damaged, aged, and pathologic tissues using minimally invasive procedures, this is likely to drive demand for platelet-rich plasma. Moreover, with clear evidence of safety, platelet-rich plasma is likely to emerge as prominent treatment and effective musculoskeletal medicine.

To view TOC of this report is available upon request @ https://www.persistencemarketresearch.com/toc/22906